Leverage
Guardant Infinity’s extensive methylation coverage to deliver more precise cancer therapeutics.¹

Epigenomic analysis can dramatically improve sensitivity in MRD detection and cancer monitoring.

Expand patient eligibility for targeted therapy

Epigenomic profiling can expand patient reach through the identification of novel biomarkers.

Enhance your ability to stratify patients

Methylation-based molecular response assessment can improve therapy response predictions when compared with genomic-only methods.

Better predict response to therapy^2-4